Comment

  • 31 January 2019

    Reimbursement setback for first-in-class drug Aimovig

    The migraine market had a landmark year in 2018, seeing the launch of three calcitonin gene-related peptide (CGRP) antagonists, a highly anticipated new class of drugs given these are specifically...

Go Top